Polycystic Ovary Syndrome: Familiar to Millions?
Funding
Conflicts of Interest
References
- Sills, E.S.; Perloe, M.; Tucker, M.J.; Kaplan, C.R.; Genton, M.G.; Schattman, G.L. Diagnostic and treatment characteristics of polycystic ovary syndrome: Descriptive measurements of patient perception and awareness from 657 confidential self-reports. BMC Womens Health 2001, 1, 3. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Diamanti-Kandarakis, E.; Baillargeon, J.P.; Iuorno, M.J.; Jakubowicz, D.J.; Nestler, J.E. A modern medical quandary: Polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J. Clin. Endocrinol. Metab. 2003, 88, 1927–1932. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Legro, R.S.; Barnhart, H.X.; Schlaff, W.D.; Carr, B.R.; Diamond, M.P.; Carson, S.A.; Steinkampf, M.P.; Coutifaris, C.; McGovern, P.G.; Cataldo, N.A.; et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N. Engl. J. Med. 2007, 356, 551–566. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tang, T.; Lord, J.M.; Norman, R.J.; Yasmin, E.; Balen, A.H. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst. Rev. 2012, CD003053. [Google Scholar] [CrossRef] [PubMed]
- Ünlütürk, U.; Sezgin, E.; Yildiz, B.O. Evolutionary determinants of polycystic ovary syndrome: Part 1. Fertil Steril 2016, 106, 33–41. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Saxena, R.; Bjonnes, A.C.; Georgopoulos, N.A.; Koika, V.; Panidis, D.; Welt, C.K. Gene variants associated with age at menopause are also associated with polycystic ovary syndrome, gonadotrophins and ovarian volume. Hum. Reprod. 2015, 30, 1697–1703. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Al Wattar, B.H.; Teede, H.; Garad, R.; Franks, S.; Balen, A.; Bhide, P.; Piltonen, T.; Romualdi, D.; Laven, J.; Thondan, M.; et al. Harmonising research outcomes for polycystic ovary syndrome: An international multi-stakeholder core outcome set. Hum. Reprod. 2020, 35, 404–412. [Google Scholar] [CrossRef] [PubMed]
- Arentz, S.; Smith, C.A.; Abbott, J.; Bensoussan, A. Nutritional supplements and herbal medicines for women with polycystic ovary syndrome; a systematic review and meta-analysis. BMC Complement. Altern. Med. 2017, 17, 500. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Saleem, F.; Rizvi, S.W. New Therapeutic Approaches in Obesity and Metabolic Syndrome Associated with Polycystic Ovary Syndrome. Cureus 2017, 13, e1844. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yurtdaş, G.; Akdevelioğlu, Y. A New Approach to Polycystic Ovary Syndrome: The Gut Microbiota. J. Am. Coll. Nutr. 2019, 12, 1–12. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ott, J. Polycystic Ovary Syndrome: Familiar to Millions? J. Clin. Med. 2021, 10, 1. https://doi.org/10.3390/jcm10010001
Ott J. Polycystic Ovary Syndrome: Familiar to Millions? Journal of Clinical Medicine. 2021; 10(1):1. https://doi.org/10.3390/jcm10010001
Chicago/Turabian StyleOtt, Johannes. 2021. "Polycystic Ovary Syndrome: Familiar to Millions?" Journal of Clinical Medicine 10, no. 1: 1. https://doi.org/10.3390/jcm10010001
APA StyleOtt, J. (2021). Polycystic Ovary Syndrome: Familiar to Millions? Journal of Clinical Medicine, 10(1), 1. https://doi.org/10.3390/jcm10010001